12 August 2021
SpeeDx receives TGA clearance PlexPCR® SARS-CoV-2
SpeeDx Pty. Ltd. announced today their PlexPCR® SARS-CoV-2* test received clearance from the Australian Therapeutic Goods Administration (TGA). Designed from...
5 August 2021
SpeeDx Expand US Operations with New Laboratory Facility
SpeeDx announced the expansion of US based operations and will initiate construction of clinical testing facilities in Austin, Texas. The...
26 July 2021
SpeeDx launches PlexPrime® SARS-CoV-2 Genotyping research reagents
SpeeDx have launched a new product line of research reagents to support reflex variant analysis for circulating SARS-CoV-2 variants of...
30 June 2021
SpeeDx and MolGen Announce Partnership for COVID-19 Test Solution
SpeeDx Pty, Ltd. and MolGen announced the signing of an agreement to collaborate on supply and distribution of clinical diagnostics...
11 May 2021
SpeeDx Receives CARB-X Funding to Develop Rapid Point-of-Care Diagnostic
SpeeDx announced it has been awarded up to US $1.8 million from CARB-X to address the rising threat of drug-resistant bacteria. Funds...
27 April 2021
Microbix & SpeeDx Form Exclusive Collaboration
Microbix Biosystems Inc. (TSX: MBX. OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, and SpeeDx Pty. Ltd. announced a...
